High Times

FDA Recognizes LSD-Equivalent Drug with ‘Breakthrough Therapy’ Label for Anxiety Relief

Encouraging outcomes from a clinical study on the LSD-analog substance MM120, or lysergide d-tartrate, have led the Food and Drug Administration (FDA) to designate it as a “breakthrough therapy” for ...
Seeking Alpha

MindMed: Breakthrough Status From The FDA For LSD Therapy

MindMed's LSD tartrate receives breakthrough therapy designation from the FDA for the treatment of generalized anxiety disorder. GAD affects a significant portion of the US population, with high costs ...
The Grand Junction Daily Sentinel

LSD A Potential Therapy For Anxiety, Early Clinical Trial Results Say

The improvements happened without any therapy done during the patients’ trip TUESDAY, Sept. 9, 2025 (HealthDay News) — "Flower power" psychedelic drugs might be a potential cure for modern anxiety, ...
The Hill

Single LSD dose provides lasting anxiety relief: Research

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to an LSD formula to treat generalized anxiety disorder after an initial study has shown that a single dose of the ...
MarketWatch

MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

Mind Medicine Inc.’s stock jumped 51.5% on Thursday after the biotech company said the Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for ...
Benzinga.com

MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds

The Food And Drug Administration has granted MindMed’s LSD treatment for generalized anxiety disorder a “breakthrough therapy” status. With new robust 12-week treatment durability data, financial ...